| Assessment Status | Rapid Review complete |
| HTA ID | 21052 |
| Drug | Bimekizumab |
| Brand | Bimzelx® |
| Indication | Treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. |
| Assessment Process | |
| Rapid review commissioned | 15/11/2021 |
| Rapid review completed | 07/01/2022 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of bimekizumab compared with the current standard of care, on the basis of the proposed price relative to currently available therapies. |
The HSE has approved reimbursement following confidential price negotiations; June 2023
